Search

Your search keyword '"DI MARCO, Vito"' showing total 773 results

Search Constraints

Start Over You searched for: Author "DI MARCO, Vito" Remove constraint Author: "DI MARCO, Vito"
773 results on '"DI MARCO, Vito"'

Search Results

2. Real-world experience with long-term albumin in patients with cirrhosis and ascites

3. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort

4. Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of Cholestasis

5. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

8. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

9. Development of a Thalassemia International Prognostic Scoring System (TIPSS)

12. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

14. Clinical outcomes of MAFLD versus NAFLD: A meta‐analysis of observational studies.

15. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis.

17. SAT-113 Long-term therapy with intravenous human albumin increase survival in patients with decompensated cirrhosis and refractory ascites

18. FRI-078-YI Long-term albumin administration in outpatients with decompensated cirrhosis and diabetes mellitus: post-hoc analysis of the ANSWER trial database

19. FRI-047-YI Predictors of ascites resolution in patients with cirrhosis receiving long-term albumin treatment. Results from a real-world study in Italy (Real-ANSWER)

20. SAT-209-YI A Markov model unveiling the impact of Resmetirom on the natural history of MASLD patients with baseline significant or severe liver fibrosis

21. Factors Associated with Primary Liver Cancer Survival in a Southern Italian Setting in a Changing Epidemiological Scenario

22. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)

24. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

25. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

26. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

29. Update of the statements on biology and clinical impact of occult hepatitis B virus infection

30. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

33. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

34. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis

35. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

37. Risk of liver-related events in metabolic dysfunction–associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria

39. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

40. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication

41. Risk of liver-related events in metabolic dysfunction–associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.

43. Epidemiological and clinical profile of HDV infected people in care in Italy: interim analysis from the ongoing PITER cohort

44. Programmed cell death 1 genetic variant and liver damage in non-alcoholic fatty liver disease

45. Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study)

46. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced non-alcoholic fatty liver disease

48. RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease

49. Risk factors for viral reactivation in patients with overt or occult HepatitisB Virus infection receiving immunosuppressive treatments: a systematic review and meta-analysis

Catalog

Books, media, physical & digital resources